Added to YB: 2025-09-17
Pitch date: 2025-09-16
NVO [bullish]
Novo Nordisk A/S
-19.93%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.3T
Pitch Price
DKK 354.86
Price Target
111.20 (-61%)
Dividend
3.91%
EV/EBITDA
8.27
P/E
10.92
EV/Sales
4.43
Sector
Pharmaceuticals
Category
turnaround
Novo Nordisk: Discounted Valuation + Early Tailwinds = Recovery Potential
NVO added to position: Down 65% from highs on competition/execution issues but turnaround signs emerging: new CEO cutting 9K roles for R&D focus, increased marketing, oral Wegovy promising vs LLY's disappointing Orforglipron, MASH approval, 132 lawsuits vs copycats, Trump tariff reduced to 15%. Trades 14x P/E vs fundamentals - 2x upside on multiple expansion.
Read full article (1 min)